» Articles » PMID: 39116881

Regulated Induced Proximity Targeting Chimeras-RIPTACs-A Heterobifunctional Small Molecule Strategy for Cancer Selective Therapies

Abstract

We describe a protein proximity inducing therapeutic modality called Regulated Induced Proximity Targeting Chimeras or RIPTACs: heterobifunctional small molecules that elicit a stable ternary complex between a target protein (TP) selectively expressed in tumor cells and a pan-expressed protein essential for cell survival. The resulting co-operative protein-protein interaction (PPI) abrogates the function of the essential protein, thus leading to death selectively in cells expressing the TP. This approach leverages differentially expressed intracellular proteins as novel cancer targets, with the advantage of not requiring the target to be a disease driver. In this chemical biology study, we design RIPTACs that incorporate a ligand against a model TP connected via a linker to effector ligands such as JQ1 (BRD4) or BI2536 (PLK1) or CDK inhibitors such as TMX3013 or dinaciclib. RIPTACs accumulate selectively in cells expressing the HaloTag-FKBP target, form co-operative intracellular ternary complexes, and induce an anti-proliferative response in target-expressing cells.

Citing Articles

Spatio-temporal control of mitosis using light via a Plk1 inhibitor caged for activity and cellular permeability.

von Glasenapp V, Almeida A, Chang D, Gasic I, Winssinger N, Gotta M Nat Commun. 2025; 16(1):1599.

PMID: 39971898 PMC: 11840123. DOI: 10.1038/s41467-025-56746-5.


Anticancer Ribosomally Synthesized and Post-Translationally Modified Peptides from Plants: Structures, Therapeutic Potential, and Future Directions.

Hwang H, Nam Y, Jang C, Kim E, Jang E, Lee Y Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852121 PMC: 11764418. DOI: 10.3390/cimb47010006.


Protein Degradation in Focus.

Zollman D, McAulay K Nat Chem Biol. 2024; 20(12):1559-1561.

PMID: 39472686 DOI: 10.1038/s41589-024-01757-4.


Dual-ligand PROTACS mediate superior target protein degradation and therapeutic efficacy .

Chen Y, Xia Z, Suwal U, Rappu P, Heino J, de Wever O Chem Sci. 2024; .

PMID: 39391379 PMC: 11462456. DOI: 10.1039/d4sc03555k.


Pooled endogenous protein tagging and recruitment for systematic profiling of protein function.

Serebrenik Y, Mani D, Maujean T, Burslem G, Shalem O Cell Genom. 2024; 4(10):100651.

PMID: 39255790 PMC: 11602618. DOI: 10.1016/j.xgen.2024.100651.


References
1.
Olivier T, Haslam A, Prasad V . Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Netw Open. 2021; 4(12):e2138793. PMC: 8672232. DOI: 10.1001/jamanetworkopen.2021.38793. View

2.
Gourisankar S, Krokhotin A, Ji W, Liu X, Chang C, Kim S . Rewiring cancer drivers to activate apoptosis. Nature. 2023; 620(7973):417-425. DOI: 10.1038/s41586-023-06348-2. View

3.
Kallioniemi O, Kallioniemi A, Kurisu W, Thor A, Chen L, Smith H . ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992; 89(12):5321-5. PMC: 49283. DOI: 10.1073/pnas.89.12.5321. View

4.
Sengsayadeth S, Savani B, Oluwole O, Dholaria B . Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. 2022; 3(Suppl 1):6-10. PMC: 9175669. DOI: 10.1002/jha2.338. View

5.
Chen L, Xie T, Wei B, Di D . Current progress in CAR-T cell therapy for tumor treatment. Oncol Lett. 2022; 24(4):358. PMC: 9478623. DOI: 10.3892/ol.2022.13478. View